In alternative embodiments, provided are pharmaceutical compositions comprising combinations of drugs, including products of manufacture and kits, and methods for using them, for treating, preventing, ameliorating, slowing the progress of, decreasing the severity of or preventing a coronavirus infection, or a COVID-19 or a 2019-nCoV (or so-called Wuhan coronavirus) infection, or an infection caused by a virus in the subfamily Orthocoronavirinae, or a virus in the family Coronaviridae, or a virus in the order Nidovirales. In alternative embodiments, combinations, or cocktails, of a drug or drugs as provided herein are administered either enterally, parenterally and/or by inhalation. In alternative embodiments, combinations, or cocktails, of drugs as provided herein are used to block intracellular metabolic pathways and prevent progression of the infection to clinical illness and death. In alternative embodiments, novel aerosol or powder formulations for inhalation are provided. In alternative embodiments, provided are therapeutic combinations of drugs or a drug, a pharmaceutical dosage form, a drug delivery device, or a product of manufacture, comprising: opaganib or YELIVA™, or opaganib or YELIVA™ and oral and/or inhaled chloroquine (or ARALEN™), chloroquine phosphate, chloroquine diphosphate and/or hydroxychloroquine (e.g., PLAQUENIL™), wherein optionally each or both of the opaganib and the chloroquine (or ARALEN™), chloroquine phosphate, chloroquine diphosphate and/or hydroxychloroquine (e.g., PLAQUENIL™) are in or formulated as a formulation for inhalation, for example, formulated as an aerosol, liquid or powder.

Concentrated vapors from botanical essential oils are inhaled to prevent, treat and cure infections of the respiratory pathogens causing Severe Acute Respiratory Syndrome (“SARS”). These vapors are inhaled as a practical method to reduce the risks of infection by the pathogens causing SARS in crowded public places. These vapors are also inhaled as a practical method to reduce the risks of infection by unknown, and unpredictable, respiratory pathogens that may be present in public places. The essential oils have antiseptic properties, are safe to inhale, and include, but are not limited to, the essential oils from Eucalyptus globulus, Melaleuca alternifolia, Eucalyptus citriodora, and Eucalyptus radiata. Convenient hand-held inhaler apparatus are provided for the inhalation of concentrated vapors from the antiseptic essential oils and other substances. The antiseptic essential oils have selected antiviral, antibacterial, and antifungal properties.

In alternative embodiments, provided are pharmaceutical compositions comprising combinations of drugs, including products of manufacture and kits, and methods for using them, for treating, preventing, ameliorating, slowing the progress of, decreasing the severity of or preventing a coronavirus infection, or a COVID-19 or a 2019-nCoV (or so-called Wuhan coronavirus) infection, or an infection caused by a virus in the subfamily Orthocoronavirinae, or a virus in the family Coronaviridae, or a virus in the order Nidovirales. In alternative embodiments, combinations, or cocktails, of a drug or drugs as provided herein are administered either enterally, parenterally and/or by inhalation. In alternative embodiments, combinations, or cocktails, of drugs as provided herein are used to block intracellular metabolic pathways and prevent progression of the infection to clinical illness and death. In alternative embodiments, novel aerosol, spray or mist or powder formulations for inhalation are provided. In alternative embodiments, provided are therapeutic combinations of drugs or a drug, a pharmaceutical dosage form, a drug delivery device, or a product of manufacture, comprising: opaganib or YELIVA™, or opaganib or YELIVA™ and oral and/or inhaled chloroquine (or ARALEN™) chloroquine phosphate, chloroquine diphosphate and/or hydroxychloroquine (optionally, PLAQUENIL™), with or without azithromycin, wherein optionally each or all of the opaganib, the chloroquine (or ARALEN™), chloroquine phosphate, chloroquine diphosphate and/or hydroxychloroquine (optionally, PLAQUENIL™), and/or azithromycin, and others, are in or formulated as a formulation for inhalation, for example, formulated as an aerosol, spray, mist, liquid or powder.

The present invention relates to the administration of active substances with antiviral, antimalarial and/or mucolytic properties, or pharmaceutically acceptable derivatives thereof for the treatment of viral lung diseases, especially COVID-19 by means of soft mist inhaler or vibrating mesh technology (VMT) nebulizer through inhalation. The present invention particularly relates to the administration of favipiravir, mannitol, hydroxychloroquine, umifenovir, molnupiravir, pimodivir, and/or remdesivir, and/or their water-soluble salt forms, and/or their water-soluble cyclodextrin complexes, and/or their water-soluble forms obtained by water-solubility increasing methods in the treatment of viral lung diseases, especially COVID-19 by means of soft mist inhaler or vibrating mesh technology (VMT) nebulizer through inhalation. Active substances with antiviral, antimalarial, and/or mucolytic properties reach the lungs efficiently and quickly, and local pulmonary administration is performed such that it provides an effective treatment. Since the drug is targeted directly to the lungs without getting into systemic circulation via local (direct) administration, its concentration is higher at the application region, thereby reducing the side effects and costs per application of the drug, and increasing its efficacy.